ProQR Therapeutics is a clinical-stage company developing RNA editing medicines with its Axiomer platform, led by AX-0810 and AX-0811 for cholestatic liver diseases; none are approved.
ProQR's case rests on translating Axiomer RNA editing from healthy-volunteer target engagement into patient benefit. AX-0810 raised serum bile acids up to 8-fold at 6 mg/kg, exceeding the predefined 2-fold threshold. Initial biliary atresia and AX-0422 patient data are expected in the first half of 2027; AX-0811 target-engagement data are expected in early January 2027. The completed $59.2 million financing supports management's runway guidance through mid-2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: NTCP editing shows benefit in patients
Does NTCP editing improve liver measures with acceptable safety in pediatric biliary atresia?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
ProQR's RNA editing case turns on patient benefit after initial target engagement
AX-0810 posts clean Phase 1 target engagement with Lilly investment and fresh capital, but biliary atresia Phase 2 data won't arrive until mid-2028
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Liver and digestive diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
3 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.